You are here

AAV-based toolkit for targeting specific cell types

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43NS077514-01
Agency Tracking Number: R43NS077514
Amount: $674,728.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NINDS
Solicitation Number: PA11-134
Timeline
Solicitation Year: 2012
Award Year: 2012
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
235 GERRY RD
BROOKLINE, MA -
United States
DUNS: 966917564
HUBZone Owned: No
Woman Owned: Yes
Socially and Economically Disadvantaged: No
Principal Investigator
 LUDMILA GERASHCHENKO
 (617) 327-0234
 ludmila_gerashchenko@hotmail.com
Business Contact
 LUDMILA MD
Phone: (617) 327-0234
Email: ludmila_gerashchenko@hotmail.com
Research Institution
 Stub
Abstract

DESCRIPTION (provided by applicant): Our goal is to develop an efficient and inexpensive toolkit for ablating or reversibly inactivating specific cell types in the brain or other organs of mammals. We propose new techniques in which the genes for nitroreductase (NTR) or Drosophila allatostatin receptor (AlstR) are delivered into cells using an adeno-associated viral vector (AAV). Both are fusion proteins linked to enhanced green fluorescent protein (EGFP), making it easy to identify transfected cells. Thetransfected cells are then either ablated by an i.p. injection of CB1954 or inactivated by a local injection of allatostatin. These new methods provide several advantages over related techniques such as optogenetics or ablation of cells using cytotoxins (e.g. saporin) conjugated to antibodies or ligands. These benefits include a high selectivity of cell targeting, a relatively low cost for the kit's components, and no requirement for expensive equipment. Another advantage is that AAVs efficiently transfectmammalian cells and can be used under BSL1, the biosafety level approved in most biological laboratories. With these advantages, we expect that our toolkit will be used in many labs to efficiently test the physiological functions of different cell types.To achieve high selectivity f cell targeting, these techniques use transgenic mice expressing Cre recombinase under control of cell-specific promoters. Cre-Lox recombination involves the targeting of specific sequences of DNA that are flanked by loxP sites. This recombination can splice out or invert the DNA fragment between the loxP sites. In our proposed studies, Cre recombinase will either splice out a STOP cassette or invert the insert sequence into the sense direction, allowing the expression of foreign genes only in targeted cells. The Specific Aims of the proposed project are to: 1. Construct AAV vectors that enable robust expression of nitroreductase and allatostatin receptor selectively in cells containing Cre recombinase. 2. Test the constructedAAV vectors in several lines of Cre-expressing mice and identify the most efficient protocol for ablation or inactivation f the Cre-containing cells. We believe that our toolkit will be of great help to the research community due to the unique and powerful features of the method. PUBLIC HEALTH RELEVANCE: We propose to develop an efficient and inexpensive toolkit for ablating or reversibly inactivating specific cell types in the brain or other organs of mammals This innovative research toolkit will facilitate research and drug discovery in the neurological and metal health areas.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government